What Are the Chances of NeuBase Therapeutics Inc (NBSE) Stock Making a Comeback?
H.C. Wainwright raised the price target for the NeuBase Therapeutics Inc (NASDAQ:NBSE) stock to “a Buy”. The rating was released on February 12, 2021, according to finviz. In their research brief published November 21, 2019, Oppenheimer analysts initiated the NeuBase Therapeutics Inc stock to Outperform with a price target of $14. The latest trade, Performances […]
